Pharmacokinetics and biodistribution of genetically engineered antibodies

Curr Opin Biotechnol. 2002 Dec;13(6):603-8. doi: 10.1016/s0958-1669(02)00352-x.


The engineering of monoclonal antibodies has created a new generation of pharmaceuticals with the desired pharmacokinetics and biodistribution properties. For radioimmunotherapy and radioscintigraphy, optimum tumor targeting can be achieved using engineered constructs that provide high antigen affinity and specificity, effective tumor penetration, circulation properties that allow high tumor uptake with acceptable doses to the normal tissues, and fast clearance allowing low background. Recent advances have made possible the development of antibodies with these properties.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Animals
  • Antibodies / genetics
  • Antibodies / metabolism
  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal / pharmacokinetics*
  • Cloning, Molecular / methods
  • Humans
  • Immunoglobulin Fragments / biosynthesis
  • Immunoglobulin Fragments / metabolism*
  • Metabolic Clearance Rate
  • Mice
  • Neoplasms / metabolism*
  • Protein Engineering / methods*
  • Tissue Distribution


  • Antibodies
  • Antibodies, Monoclonal
  • Immunoglobulin Fragments